US Close 16 November 2026: S&P 500 -1.92% as New AI Chip Export Rule Sends Chipmakers Down 5.28%
S&P 500 close: 7,416.59 (-1.92%) Breadth: 109 advancers / 342 decliners Sentiment: bearish
The S&P 500 closed at 7,416.59 on 16 November 2026, down 145.08 points or 1.92%, after the Commerce Department's Bureau of Industry and Security issued a rule requiring licences for advanced AI chips sent to data centers in five countries, and the PHLX Semiconductor Index fell 5.28%. NVDA.US fell 4.12% to $156.14, a day before its first results since Jensen Huang resigned as CEO, and MU.US dropped 7.62%. The New York Fed's Empire State factory index fell 18 points to 7.8 against a 16.7 forecast.
What moved the index
The S&P 500 lost 192 bps on 16 November 2026 while the equal-weight RSP.US fell 1.01%, so the largest technology stocks accounted for most of the decline.
- Chips and AI hardware (29 names plus NVDA.US): about 17% of the index, worth about -87 bps. Memory and equipment makers averaged -5.76% (MU.US -7.62%, SNDK.US -8.58%, LRCX.US -6.68%, TSM.US -6.34%), AI hardware averaged -5.04% (AMD.US -5.58%, ORCL.US -4.99%, AVGO.US -3.92%, DELL.US -6.96%), and NVDA.US cost about 20 bps on its own. The new rule also requires a licence when large data center operators anywhere give China-headquartered companies remote access to the chips, per Fortune.
- GOOGL.US, AMZN.US and TSLA.US: -3.49% on average at about 15% of the index, worth about -53 bps. GOOGL.US fell 4.07%, AMZN.US 3.34% and TSLA.US 2.69%.
- MSFT.US, AAPL.US and META.US: about -17 bps combined. META.US fell 2.38%, MSFT.US 1.12% and AAPL.US 0.98%.
- Financials and energy: about -13 bps. GS.US -2.73%, MS.US -2.66% and JPM.US -2.31%; XOM.US -1.56% as December WTI fell 3.59% to $85.38.
Together, these drivers sum to about -170 bps of the -192 bps move; the other 349 large caps make up the rest, with 92 higher and 257 lower. Consumer staples added about +2 bps and health care about -3 bps.
Session highlights
The S&P 500 traded between 7,400.15 and 7,515.60 on 16 November 2026 and closed 16.44 points above the session low.
- 24,509.76 was the Nasdaq Composite close, down 626.52 points or 2.49%, its third straight decline, per CNBC. The Dow fell 739.38 points or 1.41% to 51,608.17, and the Russell 2000 fell 1.70% to 2,742.94.
- 22.91 was the VIX close, up 18.73% from 19.30.
- 90 days is the time data centers already serving China-headquartered companies have to obtain a licence under the interim final rule, which covers Indonesia, Malaysia, Singapore, Thailand and Brazil, per Fortune.
- 10% is how far NVDA.US closed below its 11 November close; Nvidia said on 12 November that Huang had resigned and finance chief Colette Kress became interim CEO, per StockTitan.
- 5.121% was the 10-year Treasury yield, down from 5.154%. DXY rose 0.19% to 103.61.
- $65,168 was bitcoin, up 0.30%. MSTR.US fell 7.70%, COIN.US 6.11% and HOOD.US 7.45%.
- $3,855.20 was December gold, down 0.80%, and December silver fell 4.49% to $46.92.
Sector scorecard
XLP.US led the SPDR sector funds on 16 November 2026 at +0.27%, and XLK.US fell furthest at -3.24%; only two of eleven funds closed higher.
- Best: Consumer Staples, XLP.US (+0.27%)
- Worst: Technology, XLK.US (-3.24%)
- Dispersion (best minus worst): 3.51 pts
- Also higher: XLU.US +0.18%
- Also lower: XLE.US -1.96%, XLI.US -1.85%, XLC.US -1.72%, XLY.US -1.53%, XLB.US -1.46%, XLF.US -0.85%, XLV.US -0.51%, XLRE.US -0.27%
- SMH.US fell 5.11% while PG.US gained 1.90% and KMB.US 1.75%
Top movers
CG Oncology led US-listed stocks above $2 billion in value on 16 November 2026 at +13.95%, and Summit Therapeutics fell furthest at -16.47%.
| Ticker | Move | Reason |
|---|---|---|
| CGON.US | +13.95% | Phase 3 bladder cancer trial cut recurrence risk 68%, per StockTitan |
| TU.US | +12.19% | Confirmed an unsolicited takeover proposal from Québecor |
| TSN.US | +8.72% | Q4 adjusted EPS $0.61, down 47%; guided fiscal 2027 sales lower |
| CNC.US | +4.91% | Managed care rose: HUM.US +2.50%, UNH.US +1.12% |
| LUV.US | +3.34% | Unannounced, likely flow-driven. |
| SMMT.US | -16.47% | FDA complete response letter for ivonescimab in lung cancer |
| ACCV.US | -12.93% | Unannounced, likely flow-driven. |
| NVTS.US | -11.96% | Fell with chipmakers; PHLX Semiconductor Index -5.28% |
| IREN.US | -9.80% | AI data center names fell: NBIS.US -7.55%, CRWV.US -6.12% |
| NTRA.US | -9.59% | Unannounced, likely flow-driven. |
After-hours earnings
- INFQ.US: third-quarter revenue rose 25% to $9.1 million and Infleqtion kept its 2026 outlook of at least $45.1 million; shares rose 0.8% after hours, per Investing.com, after a 6.84% fall in the regular session.
- No large reports: Faraday Future, Daré Bioscience and Firy were the other scheduled reporters, per TipRanks.
Notable announcements
- Empire State survey: the November general business conditions index fell 18 points to 7.8, still above zero, per the New York Fed.
- HELP.US: fell 13.53% after its Phase 3 depression trial met its main goal but reported three serious drug-related side effects, per StockTitan.
- LXEO.US: rose 12.54% after early heart gene therapy data and FDA openness to a heart rhythm trial goal, per StockTitan.
Next session catalysts (ET)
- Tue 17 Nov, 8:30am: October retail sales.
- Tue 17 Nov, about 4:20pm: Nvidia third-quarter results, its first under interim CEO Kress, per StockTitan.
- Wed 18 Nov: Anthropic expects to price its IPO, with Nasdaq trading under ANT from Thursday 19 Nov, per Investopedia.
- Wed 18 Nov: PANW.US results.
Context only, not financial advice. Track your own trades with Swingfolio.